Real-world studies have shown that adding cell therapy PROVNGE (sipuleucel-T) to advanced prostate cancer treatment options can extend the medium survival by 14.5 months.

Dendreon Pharmaceuticals conducted a real-world study of more than 6,000 male patients with metastatic degenerative degenerative prostate (mCRPC), adding cell therapy PROFENGE (sipuleucel-T) to commonly prescribed drugs (abiraterone acetate and enzalutamide) to reduce the risk of death by 41% and extend the medium total survival period (OS) by 14.5 months.
R. McKay, a medical oncologist at the Moores Cancer Center at the University of California, San Diego, said, "Based on our analysis, male MCRPC patients treated with sipuleucel-T, regardless of the drug used, had significantly improved overall survival rates and a reduced risk of death.
data provide evidence of the actual efficacy of sipuleucel-T in mCRPC patients.
. Bruce A. Brown, Chief Medical Officer, Dendreon, said, "This analysis demonstrates the importance of using complementary strategies to maximize patient survival and highlights the critical role of immunotherapy in mCRPC therapy.
" about PROPVENGE (sipuleucel-T) PROVENGE is the only FDA-approved immunotherapy for prostate cancer using patient autoimmune cells.
nearly 40,000 men have been treated with PROFVENGE and have been clinically proven to extend the lives of some men in the advanced stages of the disease.
Photo Source: The Provenge vaccine works by separating a patient's dedy cells, an immune cell that presents antigens to T cells, interacting with prostate tumor antigens in vitro and then returning them to the patient to better identify and attack prostate cancer.
picture source: